Asunto(s)
Manejo de la Enfermedad , Angiografía con Fluoresceína/métodos , Retina/diagnóstico por imagen , Tomografía de Coherencia Óptica/métodos , Síndrome Uveomeningoencefálico/diagnóstico , Agudeza Visual , Diagnóstico Diferencial , Femenino , Fondo de Ojo , Humanos , Síndrome Uveomeningoencefálico/terapia , Adulto JovenAsunto(s)
Endotaponamiento/métodos , Desprendimiento de Retina/cirugía , Perforaciones de la Retina/cirugía , Agudeza Visual , Vitrectomía/métodos , Anciano , Anciano de 80 o más Años , Femenino , Estudios de Seguimiento , Humanos , Mácula Lútea/diagnóstico por imagen , Mácula Lútea/cirugía , Masculino , Persona de Mediana Edad , Desprendimiento de Retina/diagnóstico , Perforaciones de la Retina/diagnóstico , Estudios RetrospectivosRESUMEN
PURPOSE: To draw attention to a novel treatment agent for vision loss associated with peripheral exudative hemorrhagic chorioretinopathy. METHODS: The case of an 83-year-old man suffering with loss of left visual acuity vision in the context of vitreous hemorrhage secondary to peripheral exudative hemorrhagic chorioretinopathy is described. RESULTS: Resolution of vitreous hemorrhage and subretinal hemorrhage was demonstrated after treatment with aflibercept. CONCLUSION: Peripheral exudative hemorrhagic chorioretinopathy is discussed in terms of its presentation, pathophysiology, and existing treatment methodologies.
Asunto(s)
Inhibidores de la Angiogénesis/uso terapéutico , Coriorretinopatía Serosa Central/tratamiento farmacológico , Receptores de Factores de Crecimiento Endotelial Vascular/uso terapéutico , Proteínas Recombinantes de Fusión/uso terapéutico , Hemorragia Retiniana/tratamiento farmacológico , Hemorragia Vítrea/tratamiento farmacológico , Anciano de 80 o más Años , Coriorretinopatía Serosa Central/diagnóstico , Coriorretinopatía Serosa Central/fisiopatología , Exudados y Transudados , Humanos , Inyecciones Intravítreas , Masculino , Hemorragia Retiniana/diagnóstico , Hemorragia Retiniana/fisiopatología , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Agudeza Visual/fisiología , Hemorragia Vítrea/diagnóstico , Hemorragia Vítrea/fisiopatologíaRESUMEN
PURPOSE: This study explores autologous neurosensory autograph for a patient with a chronic full-thickness macular hole (FTMH) and idiopathic macular telangiectasia type 2 (IMT2). OBSERVATIONS: The patient had a chronic 1355 µm FTMH and best corrected visual acuity (BCVA) of 2 logMAR units after two unsuccessful attempts to close the macular hole. Following a 25-gauge vitrectomy, a 2-disc diameter neurosensory autograft from the supertemporal retina was mobilized and secured with perfluoro-N-octane (PFO) tamponade. After being postured supine for one week, the PFO was exchanged for silicone oil. Two months later, silicone oil was exchanged for 20% sulphur hexafluoride (SF6). CONCLUSIONS AND IMPORTANCE: The graft achieved anatomical and functional success with BCVA of 0.6 logMAR units. This case supports autologous neurosensory autograph as a technique for achieving closure of chronic macular holes refractory to conventional treatment.